

# World Journal of *Gastrointestinal Oncology*

*World J Gastrointest Oncol* 2021 December 15; 13(12): 1850-2222





### FRONTIER

- 1850** Management of obstructive colon cancer: Current status, obstacles, and future directions  
*Yoo RN, Cho HM, Kye BH*

### REVIEW

- 1863** Role of endoscopic ultrasound in anticancer therapy: Current evidence and future perspectives  
*Bratanic A, Bozic D, Mestrovic A, Martinovic D, Kumric M, Ticinovic Kurir T, Bozic J*
- 1880** Pancreatic intraductal papillary mucinous neoplasms: Current diagnosis and management  
*Jabłońska B, Szmigiel P, Mrowiec S*
- 1896** Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines?  
*Sparchez Z, Radu P, Bartos A, Nenu I, Craciun R, Mocan T, Horhat A, Spârchez M, Dufour JF*
- 1919** Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures  
*Ezzat R, Eltabbakh M, El Kassas M*
- 1939** Moving forward in the treatment of cholangiocarcinoma  
*Manzia TM, Parente A, Lenci I, Sensi B, Milana M, Gazia C, Signorello A, Angelico R, Grassi G, Tisone G, Baiocchi L*
- 1956** Solid extraintestinal malignancies in patients with inflammatory bowel disease  
*Mala A, Foteinogiannopoulou K, Koutroubakis IE*
- 1981** Mesenchymal stem cell-derived exosomes for gastrointestinal cancer  
*Zhao LX, Zhang K, Shen BB, Li JN*
- 1997** Diabetes mellitus contribution to the remodeling of the tumor microenvironment in gastric cancer  
*Rojas A, Lindner C, Schneider I, González I, Araya H, Morales E, Gómez M, Urdaneta N, Araya P, Morales MA*
- 2013** Macrophages play a role in inflammatory transformation of colorectal cancer  
*Lu L, Liu YJ, Cheng PQ, Hu D, Xu HC, Ji G*

### MINIREVIEWS

- 2029** Advancement of chimeric antigen receptor-natural killer cells targeting hepatocellular carcinoma  
*Dai K, Wu Y, She S, Zhang Q*
- 2038** Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma  
*Alqahtani SA, Colombo MG*

- 2050** Endoscopic or percutaneous biliary drainage in hilar cholangiocarcinoma: When and how?  
*Mocan T, Horhat A, Mois E, Graur F, Tefas C, Craciun R, Nenu I, Spârchez M, Sparchez Z*
- 2064** Current status of non-surgical treatment of locally advanced pancreatic cancer  
*Spiliopoulos S, Zurlo MT, Casella A, Laera L, Surico G, Surgo A, Fiorentino A, de'Angelis N, Calbi R, Memeo R, Inchingolo R*
- 2076** Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy  
*Sho T, Morikawa K, Kubo A, Tokuchi Y, Kitagataya T, Yamada R, Shigesawa T, Kimura M, Nakai M, Suda G, Natsuizaka M, Ogawa K, Sakamoto N*

**ORIGINAL ARTICLE****Basic Study**

- 2088** Dysbiosis of the duodenal microbiota as a diagnostic marker for pancreaticobiliary cancer  
*Sugimoto M, Abe K, Takagi T, Suzuki R, Konno N, Asama H, Sato Y, Irie H, Watanabe K, Nakamura J, Kikuchi H, Takasumi M, Hashimoto M, Kato T, Kobashi R, Hikichi T, Ohira H*
- 2101** MutL homolog 1 methylation and microsatellite instability in sporadic colorectal tumors among Filipinos  
*Cabral LKD, Mapua CA, Natividad FF, Sukowati CHC, Cortez ER, Enriquez MLD*
- 2114** Propofol induces ferroptosis and inhibits malignant phenotypes of gastric cancer cells by regulating miR-125b-5p/STAT3 axis  
*Liu YP, Qiu ZZ, Li XH, Li EY*
- 2129** BRAF<sup>V600E</sup> mutant colorectal cancer cells mediate local immunosuppressive microenvironment through exosomal long noncoding RNAs  
*Zhi J, Jia XJ, Yan J, Wang HC, Feng B, Xing HY, Jia YT*

**Retrospective Cohort Study**

- 2149** Hepatocellular carcinoma surveillance and quantile regression for determinants of underutilisation in at-risk Australian patients  
*Low ES, Apostolov R, Wong D, Lin S, Kutaiba N, Grace JA, Sinclair M*
- 2161** Comparison of tumor regression grading systems for locally advanced gastric adenocarcinoma after neoadjuvant chemotherapy  
*Liu ZN, Wang YK, Zhang L, Jia YN, Fei S, Ying XJ, Zhang Y, Li SX, Sun Y, Li ZY, Ji JF*

**Retrospective Study**

- 2180** Clinical features of intracerebral hemorrhage in patients with colorectal cancer and its underlying pathogenesis  
*Deng XH, Li J, Chen SJ, Xie YJ, Zhang J, Cen GY, Song YT, Liang ZJ*

**Prospective Study**

- 2190** Anatomic resection improved the long-term outcome of hepatocellular carcinoma patients with microvascular invasion: A prospective cohort study  
*Zhou JM, Zhou CY, Chen XP, Zhang ZW*

**SYSTEMATIC REVIEWS**

- 2203** Minimally invasive surgical treatment of intrahepatic cholangiocarcinoma: A systematic review

*Patrone R, Izzo F, Palaia R, Granata V, Nasti G, Ottaiano A, Pasta G, Belli A*

**LETTER TO THE EDITOR**

- 2216** Gender differences in the relationship between alcohol consumption and gastric cancer risk are uncertain and not well-delineated

*Verma HK, Bhaskar L*

- 2219** Critical biomarkers of hepatocellular carcinoma in body fluids and gut microbiota

*Nath LR, Murali M, Nair B*

**ABOUT COVER**

Editorial Board Member of *World Journal of Gastrointestinal Oncology*, Ladan Teimoori-Toolabi, MD, PhD, Associate Professor, Department of Molecular Medicine, Pasteur Institute of Iran, Tehran 1316943551, Iran.  
iteimoori@pasteur.ac.ir

**AIMS AND SCOPE**

The primary aim of *World Journal of Gastrointestinal Oncology* (WJGO, *World J Gastrointest Oncol*) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, etc.

**INDEXING/ABSTRACTING**

The WJGO is now indexed in Science Citation Index Expanded (also known as SciSearch®), PubMed, PubMed Central, and Scopus. The 2021 edition of Journal Citation Reports® cites the 2020 impact factor (IF) for WJGO as 3.393; IF without journal self cites: 3.333; 5-year IF: 3.519; Journal Citation Indicator: 0.5; Ranking: 163 among 242 journals in oncology; Quartile category: Q3; Ranking: 60 among 92 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO's CiteScore for 2020 is 3.3 and Scopus CiteScore rank 2020: Gastroenterology is 70/136.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: Ying-Yi Yuan; Production Department Director: Xiang Li; Editorial Office Director: Ya-Juan Ma.

**NAME OF JOURNAL**

*World Journal of Gastrointestinal Oncology*

**ISSN**

ISSN 1948-5204 (online)

**LAUNCH DATE**

February 15, 2009

**FREQUENCY**

Monthly

**EDITORS-IN-CHIEF**

Rosa M Jimenez Rodriguez, Pashtoon M Kasi, Monjur Ahmed, Florin Burada

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/1948-5204/editorialboard.htm>

**PUBLICATION DATE**

December 15, 2021

**COPYRIGHT**

© 2021 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>



Retrospective Cohort Study

# Hepatocellular carcinoma surveillance and quantile regression for determinants of underutilisation in at-risk Australian patients

Elizabeth SL Low, Ross Apostolov, Darren Wong, Sandra Lin, Numan Kutaiba, Josephine A Grace, Marie Sinclair

**ORCID number:** Elizabeth SL Low 0000-0002-0604-3920; Ross Apostolov 0000-0002-4827-8795; Darren Wong 0000-0003-1490-0547; Sandra Lin 0000-0001-8959-1828; Numan Kutaiba 0000-0003-4627-9847; Josephine A Grace 0000-0002-8435-4740; Marie Sinclair 0000-0003-0657-3048.

**Author contributions:** Low ES, Apostolov R, Lin S and Kutaiba N directly designed and performed the study, with contribution from Sinclair M, Wong D and Grace J; Low ESL, Lin S and Wong D collated and analysed the data; Low ESL wrote the paper, with revisions and editing by all other listed authors.

**Institutional review board statement:** This study was approved by the Austin Health Research Ethics Committee (ID 19/114) and carried out in line with the National Statement on Ethical Conduct in Human Research (2007).

**Informed consent statement:** All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment.

**Conflict-of-interest statement:** The

Elizabeth SL Low, Ross Apostolov, Darren Wong, Josephine A Grace, Marie Sinclair, Department of Gastroenterology and Liver Transplant Unit, Austin Health, Heidelberg 3084, Victoria, Australia

Ross Apostolov, Josephine A Grace, Marie Sinclair, Department of Medicine, University of Melbourne, Melbourne 3000, Victoria, Australia

Sandra Lin, Department of Radiology, Monash Health, Clayton 3168, Victoria, Australia

Numan Kutaiba, Department of Radiology, Austin Health, Heidelberg 3084, Victoria, Australia

**Corresponding author:** Elizabeth SL Low, MBBS, Doctor, Department of Gastroenterology and Liver Transplant Unit, Austin Health, 145 Studley Road, Heidelberg 3084, Victoria, Australia. [elizabeth\\_low312@hotmail.com](mailto:elizabeth_low312@hotmail.com)

## Abstract

### BACKGROUND

While clinical guidelines recommend hepatocellular carcinoma (HCC) surveillance for at-risk individuals, reported surveillance rates in the United States and Europe remain disappointingly low.

### AIM

To quantify HCC surveillance in an Australian cohort, and assess for factors associated with surveillance underutilisation.

### METHODS

All patients undergoing HCC surveillance liver ultrasounds between January 1, 2018 to June 30, 2018 at a tertiary hospital in Melbourne, Australia, were followed until July 31, 2020, or when surveillance was no longer required. The primary outcome was the percentage of time up-to-date with HCC surveillance (PTUDS). Quantile regression was performed to determine the impact of factors associated with HCC surveillance underutilisation.

### RESULTS

Among 775 at-risk patients followed up for a median of 27.5 months, the median PTUDS was 84.2% (IQR: 66.3%-96.3%). 85.0% of patients were followed up by specialist gastroenterologists. Amongst those receiving specialist care, quantile

authors declare no conflicts of interest or financial supports.

**Data sharing statement:** Patient consent was not obtained but the presented data are anonymised and risk of identification is low. No additional data are available.

**Country/Territory of origin:**  
Australia

**Specialty type:** Gastroenterology and hepatology

**Provenance and peer review:**  
Invited article; Externally peer reviewed.

**Peer-review report's scientific quality classification**

Grade A (Excellent): A  
Grade B (Very good): B  
Grade C (Good): C  
Grade D (Fair): D  
Grade E (Poor): E

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Received:** April 16, 2021

**Peer-review started:** April 16, 2021

**First decision:** June 27, 2021

**Revised:** July 13, 2021

**Accepted:** September 19, 2021

**Article in press:** September 19, 2021

**Published online:** December 15, 2021

**P-Reviewer:** Barabino M, Parente A, Tolunay HE

**S-Editor:** Wang LL

**L-Editor:** A

**P-Editor:** Guo X



regression demonstrated differential associations at various quantile levels of PTUDS for several factors. Older age at the 25<sup>th</sup> quantile (estimate 0.002 per percent,  $P = 0.03$ ), and cirrhotic status at the 75<sup>th</sup> quantile (estimate 0.021,  $P = 0.017$ ), were significantly associated with greater percentage of time up-to-date. African ethnicity (estimate -0.089,  $P = 0.048$ ) and a culturally and linguistically diverse (CALD) background (estimate -0.063,  $P = 0.01$ ) were significantly associated with lower PTUDS at the 50<sup>th</sup> quantile, and again for CALD at the 75<sup>th</sup> quantile (estimate -0.026,  $P = 0.045$ ).

## CONCLUSION

While median PTUDS in this Australian cohort study was 84.2%, awareness of the impact of specific factors across PTUDS quantiles can aid targeted interventions towards improved HCC surveillance.

**Key Words:** Liver cirrhosis; Hepatitis, viral, human; Carcinoma, hepatocellular; Liver neoplasms; Early detection of cancer; Population surveillance

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** This study evaluated the uptake of liver cancer screening in a cohort of high-risk Australians, and found that on average, patients were up-to-date with their surveillance for 84.2% of the study time period. Certain factors, such as absence of cirrhosis, younger age, African ethnicity and a non-English speaking background were associated to varying degrees with lower time up-to-date with hepatocellular carcinoma screening.

**Citation:** Low ES, Apostolov R, Wong D, Lin S, Kutaiba N, Grace JA, Sinclair M. Hepatocellular carcinoma surveillance and quantile regression for determinants of underutilisation in at-risk Australian patients. *World J Gastrointest Oncol* 2021; 13(12): 2149-2160

**URL:** <https://www.wjgnet.com/1948-5204/full/v13/i12/2149.htm>

**DOI:** <https://dx.doi.org/10.4251/wjgo.v13.i12.2149>

## INTRODUCTION

Globally, hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and is the fourth leading cause of cancer-related mortality[1-3]. Over the last three decades in Australia, there has been a 306% increase in age-standardised incidence of liver cancer, and a corresponding 184% increase in attributable mortality rates[4]. These concerning escalations are mirrored in recent reports from the United States, and the age-adjusted worldwide incidence of HCC stands at 10.1 cases /100,000 person-years[5,6].

While curative treatment options offer 5-year survival rates in excess of 70%, these are only feasible at early disease stages, often when HCC is clinically silent[1,7]. A meta-analysis of cohort studies demonstrated improved early-stage detection and associated survival with HCC screening in at-risk populations[8]. This is particularly accepted in the non-cirrhotic population, for whom surgical resection is often a viable and life-saving intervention for early HCC[9]. As such, international professional societies recommend that at-risk patients undergo HCC surveillance with liver ultrasound (USS) every 6 months, with or without concurrent alpha fetoprotein (AFP) measurements[10,11].

The effectiveness of HCC surveillance relies on consistent clinical uptake of screening, particularly as sensitivity rates of ultrasonography for the detection of HCC are reported to be as low as 60%, thus requiring serial scans to ensure maximum yield [6]. However, several cohort studies have supported longstanding concerns of HCC surveillance underutilisation in clinical practice, with two recent meta-analyses reporting overall pooled adherence rates of 24% and 52% [3,12]. Research into adherence to surveillance is limited by the marked heterogeneity in the definitions of adherence in the literature[3]; studies vary from requiring perfect 6-monthly



adherence, to allowing leeway periods of up to 12 mo between imaging, raising the possibility of lost interim early-stage HCC detection[3].

To better incorporate both frequency of screening and quantity of imaging performed, the concept of 'percentage of time up-to-date with surveillance' (PTUDS) has been proposed as a more robust, continuous metric to standardise the measurement of adherence to HCC surveillance[3,7]. This retrospective cohort study aimed to quantify the percentage of time up-to-date with HCC screening in an Australian cohort of 'at-risk' patients, and to identify determinants associated with higher adherence to surveillance.

## MATERIALS AND METHODS

### Study design

This retrospective cohort study at a large tertiary hospital in Melbourne, Australia captured all at-risk patients identified by radiology records as undergoing a liver ultrasound scan (USS) for HCC surveillance within the Austin Hospital radiology department between 1 January 2018 to 30 June 2018. All USS were requested by gastroenterologists, infectious disease physicians and nurse practitioners who manage patients deemed at-risk of HCC in outpatient specialty clinics. Most at-risk patients at our centre were managed in physician-led specialty clinics. A proportion of consenting patients, who were felt to be at low risk of progressive liver disease, were primarily managed in a nurse-led, HCC screening clinic. Eligible patients for the nurse-led clinic were patients not requiring treatment for chronic hepatitis B, and patients with well-compensated cirrhosis from a disease aetiology that was considered adequately treated. All patients referred to the nurse-led clinic were previously seen by physicians and physician oversight was available if needed.

At-risk patients for HCC development were defined according to AASLD guidelines, and included those with cirrhosis irrespective of aetiology, and patients with chronic hepatitis B and additional HCC risk factors (i.e. family history of HCC, African descent, Asian males over 40 years old, Asian females over 50 years old)[10]. Our institution also performs surveillance for patients with chronic hepatitis C and advanced fibrosis (F3 and above), as HCC incidence in this demographic may surpass the threshold for cost-effective screening[6]. Patients who did not meet this criteria or had a documented history of HCC within the last 2 years were excluded.

Patients were followed-up from the index USS until July 31, 2020, or when surveillance was no longer required. Reasons for this included HCC diagnosis (after which patients were diverted into our liver cancer clinic), death, receipt of an orthotopic liver transplant, or when surveillance was no longer deemed appropriate, such as cases of elderly multi-comorbid patients with limited life expectancy. Follow-up periods were also truncated for patients who were discharged to other medical services. In these cases, follow-up end-date was documented as date of the formal discharge letter written by attending clinicians to the patient and/or their primary care physician. This acknowledged the possibility of subsequent external imaging and follow-up.

This study was approved by the Austin Health Research Ethics Committee and carried out in line with the National Statement on Ethical Conduct in Human Research (2007).

### Data collection

Patient demographics, clinical history, laboratory investigations and imaging results were extracted from their electronic medical records at the time of inclusion. Diagnoses of chronic hepatitis B were verified by record review of positive hepatitis B surface antigen or HBV DNA tests at least 6 mo apart. Confirmation of chronic hepatitis C occurred if there was evidence of positive hepatitis C antibody or viral RNA. All cirrhosis diagnoses were verified by review of clinical records by a consultant gastroenterologist, where cirrhosis was confirmed using a combination of clinical, biochemical, radiological and histological findings. Scanned medical records were also reviewed to retrieve externally performed liver imaging.

### Outcomes of interest

The primary outcome was adherence to HCC surveillance imaging. Accepted imaging modalities included targeted liver USS, or contrast-enhanced CT or MRI, given their routine use in clinical practice when USS images are inadequate. Adherence was defined as the percentage of time up-to-date with screening (PTUDS, %), calculated as



the percentage of an individual's total follow-up time in which they were within 6 mo of an accepted HCC surveillance test. This endpoint was chosen as it accounted for both number and timing of surveillance imaging performed during the screening period. Following surveillance imaging, patients were credited as having 6 mo of 'time up-to-date'. Any subsequent imaging that occurred within that 6-month period resulted in a re-set of the 6-month interval clock from the date that the new imaging was performed (Figure 1). AFP levels were recorded, but were not included in the primary outcome, given AFP testing is not considered a stand-alone surveillance test.

### Patient demographics

Demographic variables, based on literature-reported factors, were also extracted from the database and assessed for potential associations with uptake of HCC surveillance. These variables of interest included age, gender, ethnicity, primary language spoken, aetiology of liver disease, cirrhosis status and MELD score.

### Statistical analysis

Descriptive statistical analysis was reported as proportions (%) for categorical variables, and means (with standard deviations) or medians (with IQRs) for continuous variables, depending on the distribution of values. Comparative analysis was conducted using the Student t-test and Wilcoxon rank-sum tests. Univariable and multivariable quantile regression analysis was then performed to assess for factors associated with PTUDS, particularly variables with significant associations at different PTUDS quantiles. Quantile regression modelling was chosen given the non-parametric distribution of the outcome variable relative to covariates, its flexibility in assessing the relationship between determinants of surveillance and PTUDS at the upper and lower tails, and the lack of stringent model assumptions required for valid inference. The median (50<sup>th</sup>), 25<sup>th</sup>, and 75<sup>th</sup> quantiles were selected to provide a description of covariate associations across the range of the distribution of PTUDS, whilst avoiding the effect of extreme outliers. Bootstrapping was used to calculate 95% confidence intervals around the estimates. Both univariate and multivariate models were constructed separately for each of the selected PTUDS quantiles to determine if there were differential covariate associations across the distribution.

Data analysis was performed using Statistical Analysis Software (SAS) v.9.4 and R Software v.4.0.3 using the quantreg package[13,14].

## RESULTS

### Baseline characteristics

We identified 838 patients who underwent liver USS with radiology record requests for HCC surveillance within the 6-month recruitment period. On further review, 22 patients were excluded due to prior liver transplantation, 1 due to recent history (< 2 years) of HCC, 9 who did not meet criteria for screening (incorrectly classified as cirrhotic) and 31 with chronic hepatitis B who did not meet guideline criteria for surveillance. 775 patients were included in the final analysis. Baseline characteristics are detailed in Table 1.

The mean age of patients was 60.0 (standard deviation 12.2) years. The majority were male (59.0%), Caucasian (57.0%) and English-speaking (73.9%), with cirrhosis the most common indication for HCC surveillance (55.3%). Of those with cirrhosis, the median MELD score at inclusion was 9. The majority of patients were followed up in hepatology clinics (58.5% general liver, 16.3% pre-transplant, 10.3% nurse-led). The median follow-up time was 27.5 mo (IQR: 26.0-29.0 months). The most commonly used screening modality was ultrasound (86.9%), followed by contrast-enhanced CT liver (9.4%) and contrast-enhanced MRI (3.7%). AFP was performed in conjunction to imaging at least once in 91.9% of patients.

Twenty patients had an interim orthotopic liver transplant, 22 died and 41 were discharged from clinic surveillance, either due to service nonattendance (36%), transfer of care to other institutions (50%), or when surveillance was deemed no longer clinically appropriate (14%). HCCs developed in 22 patients (2.8%) over the course of the study. Of these 22 HCCs, 14 (64%) were detected at an early stage.

### Primary outcome

The median PTUDS overall was 84.2% (IQR: 66.3%-96.3%). 13.2% of patients were up-to-date for less than 50% of their surveillance time period, representing average

**Table 1 Baseline Characteristics of 775 at-risk patients participating in hepatocellular carcinoma surveillance, 2018-2020**

Characteristic	n = 775 (%)	mean ± SD	Median (IQR)
Age (years)		60.0 ± 12.2	
Sex			
Male	457 (59.0)		
Female	318 (41.0)		
Ethnicity			
Caucasian	442 (57.0)		
Asian	249 (32.1)		
African/Middle-Eastern	68 (8.8)		
Unreported	16 (2.1)		
Primary language spoken			
English	573 (73.9)		
Non-English	202 (26.1)		
Indication for hepatocellular carcinoma surveillance			
Cirrhosis	429 (55.3)		
Chronic HBV	343 (44.3)		
Chronic HCV with Advanced Fibrosis	3 (0.4)		
Aetiology of Cirrhosis, n = 429			
HBV hepatitis	58 (13.5)		
HCV hepatitis	136 (31.7)		
Alcoholic hepatitis	103 (24.0)		
NASH	64 (14.9)		
Non-viral, non-alcoholic, non-NASH cirrhosis <sup>1</sup>	68 (15.9)		
HBV anti-viral use, n = 385			
Yes	206 (53.5)		
No	179 (46.5)		
Specialty care clinic			
General hepatology <sup>2</sup>	453 (58.5)		
Pre-transplant	126 (16.3)		
Nurse-led surveillance	80 (10.3)		
Non-liver <sup>3</sup>	76 (9.8)		
Unspecified	40 (5.2)		
MELD score, n = 429			9 (7-13)

<sup>1</sup>Includes autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, cryptogenic cirrhosis.

<sup>2</sup>Includes general liver and outreach clinics.

<sup>3</sup>Includes clinics such as infectious diseases, renal, general medicine where patients received specialist care.

HBV: Hepatitis B virus; HCV: Hepatitis C virus; NASH: Non-alcoholic steatohepatitis; SD: Standard deviation.

screening intervals of less frequently than 12-monthly (see [Figure 2](#)). Only 40% of patients spent at least 90% of their follow-up period up-to-date with surveillance.

### Univariable analyses


Older age ( $\geq 60$  years old), cirrhotic status, Non-Asian ethnicity and English-speaking as the primary language correlated with higher continuous adherence to surveillance (see [Table 2](#)). Sex and the receipt of anti-viral therapy in chronic hepatitis B patients did not correlate with differences in surveillance adherence, nor did MELD score in cirrhotics.

Continuous adherence to HCC screening varied by aetiology of liver disease. Patients with non-alcoholic steatohepatitis (NASH) had higher median PTUDS (90.9%) compared to those with viral hepatitis (82.3%,  $P = 0.003$ ) and alcohol-induced liver disease (83.8%,  $P = 0.07$ ). Those with non-viral, non-alcoholic and non-NASH disease also had statistically higher continuous surveillance adherence (median PTUDS 90.8%) than their counterparts whose aetiologies were viral hepatitis ( $P = 0.0008$ ), or alcohol ( $P = 0.07$ ). There were no significant differences in median PTUDS between the patients whose HCCs were detected earlier ( $n = 14$ ), than in those with late HCC detection ( $n = 8$ ) (100% vs 95.9%,  $P = 0.73$ ).

**Table 2 Comparison of surveillance determinants associated with greater continuous hepatocellular carcinoma surveillance among 775 at-risk patients for hepatocellular carcinoma**

Factor	Hepatocellular carcinoma surveillance adherence (PTUDS)		
	< 60 yr	60 yr	<i>P</i> value
Age	80.6%	86.8%	< 0.001
	Non-cirrhotic	Cirrhotic	
Cirrhosis status	80.1%	87.3%	< 0.001
	Non-Asian	Asian	
Ethnicity	85.1%	81.2%	0.04
	English	CALD	
Primary language spoken	85.7%	80.2%	0.03
	Male	Female	
Sex	83.3%	85.6%	0.58
	Treatment naïve	Anti-viral therapy	
Hepatitis B treatment status	79.4%	82.1%	0.07

PTUDS: Percentage of time up-to-date with hepatocellular carcinoma surveillance; CALD: Culturally and linguistically diverse background.

**Figure 1 Scenario calculations of percentage of time up-to-date with surveillance.**

Analysis demonstrated significant differences in surveillance adherence based on clinic setting, with highest PTUDS for patients attending liver transplant clinics (median PTUDS 97.4%). This was significantly greater than general hepatology clinics (median PTUDS 82.4%,  $P < 0.001$ ). Of note, patients attending nurse-led screening clinics achieved continuous surveillance adherence rates that surpassed general hepatology clinics (median PTUDS 90.0%,  $P = 0.0001$ ). This was not reflected in the performance of non-hepatology clinics, which reported the lowest continuous surveillance adherence rates (median PTUDS 62.3%).

### Multivariable analysis

Multiple quantile regression analysis demonstrated that age and clinic type (subspecialty hepatology care *vs* other) had differential effects across different PTUDS quantiles. Older age ( $\geq 60$  years) increased PTUDS across all quantiles, but this




Figure 2 Distribution of participants within percentage of time up-to-date with hepatocellular carcinoma surveillance categories.

increase was only significant at lower quantiles (25<sup>th</sup> quantile parameter estimate (PE) = 0.003,  $P = 0.01$ ; 50<sup>th</sup> quantile PE = 0.002,  $P < 0.001$ ). Non-liver-specific clinic care, compared with subspecialty hepatology care, was associated with lower PTUDS across all quantiles ( $P < 0.001$ ).

The results from subgroup quantile regression analysis of patients attending liver-specific specialty clinics (85.0% of all patients) are demonstrated in Table 3. Primary language spoken, ethnicity, and cirrhosis status were shown to variably affect PTUDS across different quantiles. The association between older age and increased PTUDS was maintained only in the 25<sup>th</sup> quantile ( $P = 0.03$ ). Patients with cirrhosis had increased PTUDS compared to their non-cirrhotic counterparts at the 75<sup>th</sup> quantile ( $P = 0.02$ ). However, African ethnicity and culturally and linguistically diverse (CALD) backgrounds were both significantly associated with lower PTUDS at the 50<sup>th</sup> quantile ( $P = 0.048$  and  $P = 0.01$ ). CALD background was also a strong predictor of lower PTUDS at the 75<sup>th</sup> quantile ( $P = 0.045$ ).

## DISCUSSION

In this Australian retrospective cohort study of HCC surveillance utilisation in 775 at-risk patients, we found that average time up-to-date with 6 monthly screening was 84.2% over a median follow-up of over 2 years. However, less than half (40.8%) of patients spent at least 90% of their surveillance period up-to-date with screening, which represents a concerning proportion of patients at risk of delayed diagnosis of HCC. Younger age, non-cirrhotic status, African ethnicity and CALD background were variably associated across PTUDS quantiles with significantly decreased time up-to-date with HCC surveillance on quantile regression analysis.

Our study is one of the few that presents adherence to HCC surveillance using a continuous outcome measure, contrasting with versions of the binary categorisation of 'adherent' and 'non-adherent' of other studies[7,15-19]. Depending on definitions used, these all-or-nothing classifications potentially enforce too stringent or too lax restrictions on surveillance intervals, and distort true interpretation of HCC surveillance application in real-time clinical practice. This study has described more accurate quantification of adherence and thus better identifies patients at risk.

Given heterogeneity in the published definitions of adherence, comparisons of surveillance uptake are limited. However, Goldberg *et al*[7] reported an analysis of patients with cirrhosis, applying the PTUDS measure to characterise adherence using United States Veterans Health Administration data. This national study found a median PTUDS for surveillance by USS only as 10% (IQR: 0%-29%)[7]. The vast discrepancy in median PTUDS compared with our finding of 84.2% is likely

**Table 3** Quantile regression parameter estimates and 95% confidence intervals of factors associated with hepatocellular carcinoma surveillance adherence for the 25<sup>th</sup>, 50<sup>th</sup> and 75<sup>th</sup> quantiles of percentage of time up-to-date with surveillance

Variables	QR Estimates (95%CI)					
	25 <sup>th</sup>	P value	50 <sup>th</sup>	P value	75 <sup>th</sup>	P value
Age	0.002 (0.000, 0.004)	0.03				
African ethnicity			-0.089 (-0.177, -0.001)	0.048		
CALD			-0.063 (-0.110, -0.016)	0.01	-0.026 (-0.052, -0.001)	0.045
Cirrhotic status					0.021 (0.004, 0.039)	0.02

CALD: Culturally and linguistically diverse background.

multifactorial. First, Goldberg's study encompassed patients followed-up in both community or specialist practices, and found that number of specialist visits was the strongest predictor for greater surveillance participation[7]. Adherence rates for those in non-specialist care have historically been low, with international and limited local data showing optimal surveillance uptake of only 8.8%-27% [3,20,21]. Specialist input may serve as a surrogate marker for greater frequency of reminders for test follow-up, may select for a group of patients more engaged with healthcare, or indicate more unwell patients undergoing imaging for reasons other than surveillance[22]. In particular, hepatology care as compared to other subspecialty providers may better identify the at-risk cohort eligible for HCC screening, therefore having 85% of patients in this study engaged in hepatology clinics may explain our comparatively high PTUDS. Furthermore, our study recruited patients based on attendance at an initial HCC screening scan, which likely also represents a more informed and engaged subset of all patients requiring HCC surveillance. Our findings are, however, similar to pooled adherence surveillance estimates of 73.7% for patients enrolled in specialist care from a recent meta-analysis, associating specialist care with higher likelihood of HCC surveillance[3].

In addition to specialist gastroenterologist/hepatologist care, this study provided insight into other factors correlated with utilisation of HCC surveillance. The high continuous surveillance adherence found in nurse-led clinic-directed care lends support to the effectiveness of this model of care shown in two cohort studies[23,24]. In keeping with several prior studies, we found lower rates of surveillance in younger patients[7,19,25,26]. Studies assessing adherence by cirrhosis status echoed our finding of screening under-utilisation in patients without cirrhosis. This is potentially attributable to a higher perceived HCC risk with cirrhosis stage by patients and providers, suggesting under-recognition of screening eligibility in this group[12,22,27]. Targeted education of providers, particularly primary care physicians who follow most high-risk patients nationally, on screening guidelines that include non-cirrhotic chronic hepatitis B patients, may improve surveillance rates. Receipt of anti-viral therapy, revealed in other studies to increase the likelihood of surveillance adherence, was not significant on multivariable analysis in our cohort of chronic hepatitis B patients[16,22].

Several studies have reported lower surveillance rates in non-Caucasians, with African American/Black patients significantly less likely to receive surveillance[7,28]. African ethnicity in our cohort was similarly associated with lower PTUDS at the 50<sup>th</sup> quantile, a concerning finding given higher rates of HCC and younger age at risk within this population[21,29]. This may correlate with our lower screening uptake in patients whose primary language was not English, although to our knowledge, no studies have yet reviewed the impact on HCC screening uptake in patients whose care is provided in a primary language that is not their native tongue. However, other cancer surveillance studies have also identified language as a key barrier in CALD patients' understanding of screening rationale and participation[30,31]. An Australian qualitative study into colorectal screening uptake within culturally and linguistically diverse groups suggested that language barriers hindered otherwise willing participation[30]. A fatalistic view on cancer diagnoses, or a fear of bad luck due to cultural beliefs, were also identified as potentially modifiable barriers to screening adherence, and suggest that culturally-tailored and language-appropriate resources may need to be employed to target diverse populations[30].

In our study, a total of 22 HCCs were detected, of which 14 were early stage and amenable to curative treatment. The annual incidence rate of HCC in our cohort was 1.3 per 100 person-years. This low incidence of HCC may be due to a high proportion in our cohort of people with treated HCV, and HBV without cirrhosis, representing patients with a relatively lower incidence rate of HCC[32]. We did not find a significant difference in overall adherence in patients with HCCs detected at an earlier compared to a later stage. While our study was not powered to answer this question, it provides interesting insight into the effect of surveillance in a cohort with adherence rates closer to the ideal, and highlights the need for quality assessment of surveillance imaging.

Strengths of this study included use of the continuous variable ‘percentage of time up-to-date with surveillance’ to quantify adherence to HCC screening, and quantile regression modelling to describe covariate effects across the spectrum of PTUDS[3,28]. Our data also reflects contemporary clinical practice, with confirmation of the ‘at-risk’ history of our surveyed population. This is also the first Australian study of a large cohort, and offers a perspective on surveillance uptake in a population not hindered by costs of screening tests. Prior observational studies have raised concerns that patient-level barriers, such as costs of surveillance investigations, may contribute to poorer surveillance receipt[22,33]. While we were unable to assess socioeconomic factors, as this data was unavailable, concerns regarding financial burden of surveillance measures are likely alleviated by their cost-free nature in Australia’s healthcare system. Finally, we accounted for patient receipt of alternate, non-ultrasound imaging. This reflects a more realistic practice of clinicians accepting contrast-enhanced CT or MRI liver imaging as appropriate surveillance studies, thus obviating the performance of additional ultrasonography.

Findings from our study should be interpreted within its limitations. As with retrospective study designs, our study is limited by missing data, unmeasured confounders and selection bias. Our analysis involved patients at a single healthcare centre, and may not be generalised to other practice environments, particularly primary care settings. Secondly, patient enrolment based on an initial HCC surveillance USS attendance in a 6 mo period does not incorporate eligible but non-adherent patients, nor those qualifying for screening but who have not been identified by clinicians as at risk of HCC. As such, our adherence rates may be overestimated towards a well-informed, more inherently adherent and correctly identified cohort. However, this large study provides valuable current insight into maintenance of HCC surveillance in patients already identified to be at risk.

## CONCLUSION

In conclusion, average time-up-to-date with HCC surveillance in an at-risk Australian cohort was 84.2% following an index screening test performed for the purpose of surveillance. Subspecialty care was associated with higher subsequent adherence to surveillance imaging. Conversely, younger age, non-cirrhotic status, African ethnicity, and CALD background, were variably associated with significantly reduced PTUDS across different PTUDS quantiles. Further research into patient and system barriers towards HCC screening will provide further information regarding provider and patient factors to better guide development of appropriate and targeted interventions to increase adherence to HCC surveillance.

## ARTICLE HIGHLIGHTS

### Research background

Hepatocellular carcinoma (HCC) surveillance rates reported from the United States and Europe remain low, despite published clinical guideline recommendations. Surveillance patterns in Australia, which has the benefit a universal healthcare program, have not been clearly delineated.

### Research motivation

Patients, and evaluate factors associated with greater uptake of HCC cancer screening. In incorporating both frequency of screening and quantity of imaging performed, we aimed to have a more continuous way of standardising ‘adherence’. Identification of determinants associated with higher HCC screening adherence aims to guide further



areas for intervention.

### Research objectives

As stated above, the objectives were characterising continuous HCC surveillance adherence. This method provides a way of standardising ‘adherence’, and thus allows for equal comparison between different studies evaluating the concept of HCC screening adherence.

### Research methods

This was a retrospective cohort study that incorporated data electronic medical records to obtain patient demographics, clinical history, lab investigations and radiological imaging results. Data analysis was both on the univariate and multivariate level. In particular, quantile regression was performed for the non-parametric outcome variable, and provides greater description of covariate associations across the range of the outcome variable.

### Research results

Follow-up of 775 at-risk patients demonstrated that median time-up-to-date with HCC surveillance was 84.2%. However, different patient factors, affected HCC surveillance adherence variably across different ranges of the outcome variable percentage of time up-to-date with HCC surveillance (PTUDS). At the 25<sup>th</sup> quantile/percentile for PTUDS, older age was associated with greater HCC surveillance. At the 50<sup>th</sup> quantile, African ethnicity had lower HCC surveillance. At the 75<sup>th</sup> quantile, cirrhotic status was associated with greater adherence to surveillance. Those of culturally and linguistically diverse backgrounds had lower continuous HCC surveillance rates at both the 50<sup>th</sup> and 75<sup>th</sup> quantiles. The ramifications of these findings and identified determinants affecting HCC surveillance participation in other settings, including the primary care setting, are less clear. However, they remain very important areas for further research. In particular, addressing the impact of ethnicity and cultural and linguistic backgrounds on screening uptake may well have beneficial consequent effects in other areas of healthcare.

### Research conclusions

The study suggests specific patient and systemic factors that contribute to participation in HCC surveillance. These factors include younger age, non-cirrhotic status, African ethnicity and coming from a culturally and linguistically diverse background, which all are variably associated with lower percentage of time up-to-date with HCC surveillance.

### Research perspectives

Future research should be directed at determining interventions aimed at the factors identified in this study to be associated with reduced HCC screening adherence. Those that improve participation in HCC surveillance may well benefit from widespread implementation to improve earlier diagnosis of HCCs.

## REFERENCES

- 1 Villanueva A. Hepatocellular Carcinoma. *N Engl J Med* 2019; **380**: 1450-1462 [PMID: 30970190 DOI: 10.1056/NEJMra1713263]
- 2 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; **68**: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21492]
- 3 Wolf E, Rich NE, Marrero JA, Parikh ND, Singal AG. Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta-Analysis. *Hepatology* 2021; **73**: 713-725 [PMID: 32383272 DOI: 10.1002/hep.31309]
- 4 Cocker F, Chien Yee K, Palmer AJ, de Graaff B. Increasing incidence and mortality related to liver cancer in Australia: time to turn the tide. *Aust N Z J Public Health* 2019; **43**: 267-273 [PMID: 30958629 DOI: 10.1111/1753-6405.12889]
- 5 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin* 2020; **70**: 7-30 [PMID: 31912902 DOI: 10.3322/caac.21590]
- 6 Forner A, Reig M, Bruix J. Hepatocellular carcinoma. *Lancet* 2018; **391**: 1301-1314 [PMID: 29307467 DOI: 10.1016/S0140-6736(18)30010-2]
- 7 Goldberg DS, Taddei TH, Serper M, Mehta R, Dieperink E, Aytaman A, Baytarian M, Fox R, Hunt K, Pedrosa M, Pocha C, Valderrama A, Kaplan DE. Identifying barriers to hepatocellular carcinoma



- surveillance in a national sample of patients with cirrhosis. *Hepatology* 2017; **65**: 864-874 [PMID: 27531119 DOI: 10.1002/hep.28765]
- 8 **Singal AG**, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. *PLoS Med* 2014; **11**: e1001624 [PMID: 24691105 DOI: 10.1371/journal.pmed.1001624]
- 9 **Kanwal F**, Singal AG. Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction. *Gastroenterology* 2019; **157**: 54-64 [PMID: 30986389 DOI: 10.1053/j.gastro.2019.02.049]
- 10 **Marrero JA**, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology* 2018; **68**: 723-750 [PMID: 29624699 DOI: 10.1002/hep.29913]
- 11 **European Association for the Study of the Liver**. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J Hepatol* 2018; **69**: 182-236 [PMID: 29628281 DOI: 10.1016/j.jhep.2012.03.006]
- 12 **Zhao C**, Jin M, Le RH, Le MH, Chen VL, Wong GL, Wong VW, Lim YS, Chuang WL, Yu ML, Nguyen MH. Poor adherence to hepatocellular carcinoma surveillance: A systematic review and meta-analysis of a complex issue. *Liver Int* 2018; **38**: 503-514 [PMID: 28834146 DOI: 10.1111/liv.13555]
- 13 **SAS Institute Inc.** SAS OnDemand for Academics. Cary, NC, USA, 2021
- 14 **R Development Core Team.** Quantreg: Quantile Regression. R package version 5.85 edition. Vienna, Austria: R Foundation for Statistical Computing, 2020
- 15 **Edenvik P**, Davidsdottir L, Oksanen A, Isaksson B, Hultcrantz R, Stål P. Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice? *Liver Int* 2015; **35**: 1862-1871 [PMID: 25524812 DOI: 10.1111/liv.12764]
- 16 **Nam JY**, Lee JH, Kim HY, Kim JE, Lee DH, Chang Y, Cho H, Yoo JJ, Lee M, Cho YY, Cho Y, Cho E, Yu SJ, Kim YJ, Yoon JH. Oral Medications Enhance Adherence to Surveillance for Hepatocellular Carcinoma and Survival in Chronic Hepatitis B Patients. *PLoS One* 2017; **12**: e0166188 [PMID: 28099520 DOI: 10.1371/journal.pone.0166188]
- 17 **Singal AG**, Tiro J, Li X, Adams-Huet B, Chubak J. Hepatocellular Carcinoma Surveillance Among Patients With Cirrhosis in a Population-based Integrated Health Care Delivery System. *J Clin Gastroenterol* 2017; **51**: 650-655 [PMID: 27870642 DOI: 10.1097/MCG.0000000000000708]
- 18 **Tavakoli H**, Robinson A, Liu B, Bhuket T, Younossi Z, Saab S, Ahmed A, Wong RJ. Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma. *Dig Dis Sci* 2017; **62**: 2174-2181 [PMID: 28474143 DOI: 10.1007/s10620-017-4595-x]
- 19 **Tran SA**, Le A, Zhao C, Hoang J, Yasukawa LA, Weber S, Henry L, Nguyen MH. Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis. *BMJ Open Gastroenterol* 2018; **5**: e000192 [PMID: 29607053 DOI: 10.1136/bmjgast-2017-000192]
- 20 **Allard N**, Cabrie T, Wheeler E, Richmond J, MacLachlan J, Emery J, Furler J, Cowie B. The challenge of liver cancer surveillance in general practice: Do recall and reminder systems hold the answer? *Aust Fam Physician* 2017; **46**: 859-864 [PMID: 29101924]
- 21 **Singal AG**, Yopp A, S Skinner C, Packer M, Lee WM, Tiro JA. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. *J Gen Intern Med* 2012; **27**: 861-867 [PMID: 22215266 DOI: 10.1007/s11606-011-1952-x]
- 22 **Wang C**, Chen V, Vu V, Le A, Nguyen L, Zhao C, Wong CR, Nguyen N, Li J, Zhang J, Trinh H, Nguyen MH. Poor adherence and low persistency rates for hepatocellular carcinoma surveillance in patients with chronic hepatitis B. *Medicine (Baltimore)* 2016; **95**: e4744 [PMID: 27583921 DOI: 10.1097/MD.0000000000004744]
- 23 **Aberra FB**, Essenmacher M, Fisher N, Volk ML. Quality improvement measures lead to higher surveillance rates for hepatocellular carcinoma in patients with cirrhosis. *Dig Dis Sci* 2013; **58**: 1157-1160 [PMID: 23111632 DOI: 10.1007/s10620-012-2461-4]
- 24 **Nazareth S**, Leembruggen N, Tuma R, Chen SL, Rao S, Kontorinis N, Cheng W. Nurse-led hepatocellular carcinoma surveillance clinic provides an effective method of monitoring patients with cirrhosis. *Int J Nurs Pract* 2016; **22** Suppl 2: 3-11 [PMID: 27476494 DOI: 10.1111/ijn.12472]
- 25 **Davila JA**, Henderson L, Kramer JR, Kanwal F, Richardson PA, Duan Z, El-Serag HB. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. *Ann Intern Med* 2011; **154**: 85-93 [PMID: 21242365 DOI: 10.7326/0003-4819-154-2-201101180-00006]
- 26 **Park B**, Choi KS, Suh M, Shin JY, Jun JK. Factors associated with compliance with recommendations for liver cancer screening in Korea: a nationwide survey in Korea. *PLoS One* 2013; **8**: e68315 [PMID: 23840846 DOI: 10.1371/journal.pone.0068315]
- 27 **Wong CR**, Garcia RT, Trinh HN, Lam KD, Ha NB, Nguyen HA, Nguyen KK, Levitt BS, Nguyen MH. Adherence to screening for hepatocellular carcinoma among patients with cirrhosis or chronic hepatitis B in a community setting. *Dig Dis Sci* 2009; **54**: 2712-2721 [PMID: 19876735 DOI: 10.1007/s10620-009-1015-x]
- 28 **Singal AG**, Li X, Tiro J, Kandunoori P, Adams-Huet B, Nehra MS, Yopp A. Racial, social, and clinical determinants of hepatocellular carcinoma surveillance. *Am J Med* 2015; **128**: 90.e1-90.e7 [PMID: 25116425 DOI: 10.1016/j.amjmed.2014.07.027]

- 29 **Kew MC.** Epidemiology of hepatocellular carcinoma in sub-Saharan Africa. *Ann Hepatol* 2013; **12**: 173-182 [PMID: [23396727](#)]
- 30 **Javanparast S,** Ward PR, Carter SM, Wilson CJ. Barriers to and facilitators of colorectal cancer screening in different population subgroups in Adelaide, South Australia. *Med J Aust* 2012; **196**: 521-523 [PMID: [22571311](#) DOI: [10.5694/mja11.10701](#)]
- 31 **Ferdous M,** Goopy S, Yang H, Rumana N, Abedin T, Turin TC. Barriers to Breast Cancer Screening Among Immigrant Populations in Canada. *J Immigr Minor Health* 2020; **22**: 410-420 [PMID: [31346839](#) DOI: [10.1007/s10903-019-00916-3](#)]
- 32 **Desai A,** Sandhu S, Lai JP, Sandhu DS. Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review. *World J Hepatol* 2019; **11**: 1-18 [PMID: [30705715](#) DOI: [10.4254/wjh.v11.i1.1](#)]
- 33 **Farvardin S,** Patel J, Khambaty M, Yerokun OA, Mok H, Tiro JA, Yopp AC, Parikh ND, Marrero JA, Singal AG. Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. *Hepatology* 2017; **65**: 875-884 [PMID: [27531684](#) DOI: [10.1002/hep.28770](#)]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

